These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

79 related items for PubMed ID: 1583298

  • 1. [Intraperitoneal chemotherapy for ovarian adenocarcinoma: pharmacokinetics of cisplatin].
    Ravina JH, Szyller A, Mintz P, Ferrand S, Ciraru-Vigneron N, Zylberberg B, Bourdon R, Galliot M.
    J Gynecol Obstet Biol Reprod (Paris); 1992; 21(2):193-7. PubMed ID: 1583298
    [Abstract] [Full Text] [Related]

  • 2. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
    Han GR, Cai GF.
    Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
    [Abstract] [Full Text] [Related]

  • 3. [Intraperitoneal high dose chemotherapy as consolidation treatment for advanced ovarian carcinoma: a pilot study].
    Gladieff L, Chatelut E, Gaspard MH, Skaf R, de Forni M, Mihura J, Canal P, Bugat R.
    Bull Cancer; 1999 Apr; 86(7-8):673-7. PubMed ID: 10477384
    [Abstract] [Full Text] [Related]

  • 4. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C, Huang R, Lian L.
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
    [Abstract] [Full Text] [Related]

  • 5. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer.
    Sugiyama T, Kumagai S, Nishida T, Ushijima K, Matsuo T, Yakushiji M, Hyon SH, Ikada Y.
    Anticancer Res; 1998 Mar; 18(4B):2837-42. PubMed ID: 9713471
    [Abstract] [Full Text] [Related]

  • 6. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
    Royer B, Delroeux D, Guardiola E, Combe M, Hoizey G, Montange D, Kantelip JP, Chauffert B, Heyd B, Pivot X.
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G, Beaujard A, Garbit F, Chaduiron-Faye C, Guillaumont M, Gilly F, Baltassat P, Bressolle F.
    Anticancer Res; 2002 Mar; 22(2B):1329-36. PubMed ID: 12168946
    [Abstract] [Full Text] [Related]

  • 8. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
    Joly F, Héron JF, Kerbrat P, Chauvergne J, Rios M, Mayer F, Chinet-Charrot P, Goupil A, Lebrun-Jezekova D, Vennin D, Lhommé C, Macé-Lesec'h J, Crouet H.
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
    [Abstract] [Full Text] [Related]

  • 9. [Effects of adjuvant hyaluronidase in tumors refractory to chemotherapy. Review of the literature and pharmacokinetics of cisplatin after regional administration in animals and humans].
    Civalleri D, Esposito M, De Cian F, Balletto N, Vannozzi MO, Mondini G, Carrabetta S, Bocchio MM.
    G Chir; 1997 Apr; 18(4):175-81. PubMed ID: 9303630
    [Abstract] [Full Text] [Related]

  • 10. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route.
    Casper ES, Kelsen DP, Alcock NW, Lewis JL.
    Cancer Treat Rep; 1983 Mar; 67(3):235-8. PubMed ID: 6682012
    [Abstract] [Full Text] [Related]

  • 11. Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
    Canal P, de Forni M, Chatelut E, Chevreau C, Johnson NP, Houin G, Bugat R.
    Acta Med Austriaca; 1989 Mar; 16(3-4):84-6. PubMed ID: 2609919
    [Abstract] [Full Text] [Related]

  • 12. Clinical trials with intraperitoneal cisplatin microspheres for malignant ascites--a pilot study.
    Hagiwara A, Takahashi T, Sawai K, Sakakura C, Tsujimoto H, Osaki K, Sakakibara T, Ohyama T, Ohgaki M, Muranishi S.
    Anticancer Drug Des; 1993 Dec; 8(6):463-70. PubMed ID: 8286013
    [Abstract] [Full Text] [Related]

  • 13. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma.
    Le T, Adolph A, Krepart GV, Lotocki R, Heywood MS.
    Gynecol Oncol; 2002 May; 85(2):351-5. PubMed ID: 11972399
    [Abstract] [Full Text] [Related]

  • 14. Weekly cis-diamminedichloroplatinum(II): active third-line chemotherapy in ovarian carcinoma--a preliminary report.
    Piver MS, Lele S, Barlow J.
    Cancer Treat Rep; 1980 May; 64(12):1379-82. PubMed ID: 7193521
    [Abstract] [Full Text] [Related]

  • 15. Cis-platin-Mecy as salvage chemotherapy in recurrent advanced ovarian carcinoma.
    Belli M, Colantuoni G, Di Iorio B.
    G Ital Oncol; 1989 May; 9(1):31-3. PubMed ID: 2785083
    [Abstract] [Full Text] [Related]

  • 16. [Intraperitoneal administration of high doses of cisplatin in advanced ovarian carcinoma].
    Ptácková B, Kopecný J, Zatocil P, Anton M.
    Cesk Gynekol; 1989 Mar; 54(2):106-9. PubMed ID: 2731237
    [Abstract] [Full Text] [Related]

  • 17. [Pharmacokinetics and toxicological study on the intraperitoneal administration of cisplatin and etoposide in gynecological malignancies].
    Fujimoto R, Yanagawa Y, Yamada T, Ueki K, Takahara T, Kumagai K, Okamura S, Ueki M, Sugimoto O.
    Gan To Kagaku Ryoho; 1992 Sep; 19(11):1843-9. PubMed ID: 1519927
    [Abstract] [Full Text] [Related]

  • 18. Intraperitoneal cis-platinum as salvage therapy for refractory epithelial ovarian cancer.
    Hacker NF, Berek JS, Pretorius RG, Zuckerman J, Eisenkop S, Lagasse LD.
    Obstet Gynecol; 1987 Nov; 70(5):759-64. PubMed ID: 3658287
    [Abstract] [Full Text] [Related]

  • 19. An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer.
    Berry E, Matthews KS, Singh DK, Buttin BM, Lurain JR, Alvarez RD, Schink J.
    Gynecol Oncol; 2009 Apr; 113(1):63-7. PubMed ID: 19201457
    [Abstract] [Full Text] [Related]

  • 20. [Intraperitoneal (Ip) high-dose cisplatinum (CDDP) chemotherapy in patients with advanced ovarian cancer].
    Noda T, Saitoh S, Ando Y, Nakanishi A, Maruya C, Yoh S, Hino K, Kiyozuka Y, Ichijo M.
    Nihon Gan Chiryo Gakkai Shi; 1985 May 20; 20(4):797-807. PubMed ID: 4056550
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.